Cargando…
Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
Coronavirus disease 2019 (COVID-19) continues to pose a threat to public health with the potential for the emergence of new variants. Vaccines are the milestones to control and slow down the damage of the pandemic. As of January 2021, a two-dose regimen with CoronaVac was authorized in Turkey. Due t...
Autores principales: | Sonmezer, Meliha Cagla, Dizman, Gulcin Telli, Erul, Enes, Sahin, Taha Koray, Saricaoglu, Tuğba, Alp, Alparslan, Tanriover, Mine Durusu, Uzun, Omrum, Unal, Serhat, Akova, Murat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322864/ https://www.ncbi.nlm.nih.gov/pubmed/35891304 http://dx.doi.org/10.3390/vaccines10071140 |
Ejemplares similares
-
CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021) -
Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021) -
A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023) -
Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)